Brian Lian, CEO, Viking Therapeutics: Great ... And then finally we have an amylin agonist that’s a little earlier. We plan to file an IND with this program later this year.

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

The new results with a once-weekly subcutaneous injection of amycretin – which is also being developed in a daily oral formulation – show that the combined GLP-1 and amylin agonist achieved up ...